On November 12, 2019 Oncology Venture A/S ("OV" or the Company) reported an update on the progress of its planned Phase 2 clinical trial for IXEMPRA (Ixabepilone) for the treatment of breast cancer (Press release, Oncology Venture, NOV 13, 2019, View Source [SID1234551165]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
OV holds an exclusive option to in-license the European rights to IXEMPRA (ixabepilone) from the pharmaceutical company R-Pharm U.S., LLC, which previously acquired global rights to the drug from Bristol-Myers Squibb (BMS). The drug is approved in the USA since 2007 for the treatment of breast cancer. OV has recently announced this drug as one of its top priority programs.
The Company is currently advancing a protocol to evaluate IXEMPRA for the treatment of newly diagnosed breast cancer (neoadjuvant setting) in a DRP-guided Phase 2 clinical trial, with sites planned in Europe. The Company’s protocol aims towards an enrollment target of nearly 40 patients. Through use of DRP patient selection, OV aims to provide a superior clinical benefit, to breast cancer patients receiving IXEMPRA, as compared to other approved therapy options. Enrollment of patients is expected in 1H 2020
Steve R. Carchedi, CEO of Oncology Venture, commented "We are pleased to announce the ongoing progress of our planned Phase 2 clinical trial for IXEMPRA, one of our top priority pipeline programs. Phase 2 development of this asset in EU positions us to advance the drug to market and commercialization in both of these top, global oncology markets. The potential approval and use of microtubulin inhibitors, such as IXEMPRA in the front-line setting for breast cancer is an exciting therapeutic area. We are confident our Phase 2 study will prove the merits of this drug, together with its DRP companion diagnostic, as we advance towards approval and commercialization of this priority asset in our pipeline."